Cit­ing pan­dem­ic, Sarep­ta de­fers much-an­tic­i­pat­ed DMD gene ther­a­py PhI­II, will head to reg­u­la­tors af­ter 10-per­son study

When Sarep­ta dis­closed in Sep­tem­ber that the FDA held up their wide­ly-an­tic­i­pat­ed Phase III tri­al over an as­say, the big ques­tion was whether the set­back might al­low Pfiz­er to over­take them in the heat­ed race to de­vel­op a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy.

On Thurs­day, though, Sarep­ta’s CEO Doug In­gram end­ed any spec­u­la­tion on the top­ic, by an­nounc­ing the com­pa­ny would de­fer its Phase III study al­to­geth­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER